Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2020, with a specific reporting date of November 12, 2020. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share acquisition transactions.
| Instrument | Transaction Type | Price per Share | Total Volume | Transaction Date |
|---|---|---|---|---|
| Ordinary Shares (25p each) | Acquisition under Share Reward Plan | £14.6231 | 16 to 18 shares per individual | 2020-11-10 |
Transactions were executed on the London Stock Exchange (XLON). The volume per individual consisted of partnership shares and matching shares (typically 9 of each, totaling 18, or 8 of each, totaling 16).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly reports routine compliance notifications for share acquisitions by senior executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a regulatory disclosure of specific equity transactions.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs and PCAs on November 10, 2020, to ensure compliance with the Share Reward Plan.
- Confirm the transaction price of £14.6231 aligns with the market price on the London Stock Exchange for that date.
- Note that this filing does not reflect the company's broader financial performance; refer to Form 20-F or quarterly reports for revenue and earnings data.